Conatumumab Biosimilar – Anti-TNFRSF10B, CD262 mAb – Research Grade

Description of Conatumumab Biosimilar - Anti-TNFRSF10B, CD262 mAb - Research Grade

Structure of Conatumumab Biosimilar – Anti-TNFRSF10B, CD262 mAb

Conatumumab Biosimilar, also known as Anti-TNFRSF10B or CD262 mAb, is a monoclonal antibody that has been developed as a biosimilar to the original drug Conatumumab. This biosimilar is designed to target TNFRSF10B, also known as Death Receptor 5 (DR5), which is a member of the tumor necrosis factor receptor superfamily. The structure of Conatumumab Biosimilar is similar to that of the original drug, with slight differences due to the biosimilar manufacturing process.

The Conatumumab Biosimilar antibody is composed of two heavy chains and two light chains, which are held together by disulfide bonds. The heavy chains have a molecular weight of approximately 50 kDa, while the light chains have a molecular weight of approximately 25 kDa. The antibody has a total molecular weight of approximately 150 kDa. The heavy and light chains are arranged in a Y-shaped structure, with the antigen-binding sites located at the tips of the Y.

Activity of Conatumumab Biosimilar – Anti-TNFRSF10B, CD262 mAb

The primary activity of Conatumumab Biosimilar is its ability to bind to TNFRSF10B/DR5, which is expressed on the surface of many tumor cells. This binding activates the apoptotic pathway, leading to cell death. In addition, Conatumumab Biosimilar also has the ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). These mechanisms further enhance the anti-tumor activity of the antibody.

In preclinical studies, Conatumumab Biosimilar has shown potent anti-tumor activity against a variety of cancer cell lines, including lung, breast, colon, and prostate cancer. It has also been shown to have synergistic effects when combined with other anti- cancer agents, such as chemotherapy and targeted therapies.

Application of Conatumumab Biosimilar – Anti-TNFRSF10B, CD262 mAb

Conatumumab Biosimilar is currently being developed as a potential treatment for various types of cancer. It is being investigated in clinical trials for its efficacy and safety in patients with advanced solid tumors, including non-small cell lung cancer, breast cancer, and colorectal cancer.

The potential of Conatumumab Biosimilar as a therapeutic agent is promising, as it specifically targets TNFRSF10B/DR5, which is overexpressed in many types of cancer. This makes it a potential treatment option for patients who do not respond to traditional therapies or have developed resistance to current treatments.

In addition to its potential as a stand-alone therapy, Conatumumab Biosimilar may also have a role in combination with other anti- cancer agents. Its ability to enhance the activity of other therapies makes it a promising candidate for combination treatment strategies.

In conclusion, Conatumumab Biosimilar – Anti-TNFRSF10B, CD262 mAb is a monoclonal antibody with a similar structure to the original drug, Conatumumab. It has potent anti-tumor activity and is being investigated as a potential treatment for various types of cancer. Its ability to specifically target TNFRSF10B/DR5 and enhance the activity of other anti- cancer agents make it a promising therapeutic option for patients with advanced solid tumors.